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Background and Purpose: The level of hypoxia in primary tumors has been described to influence response to treatment. The 
aim of the present study was to investigate the impact of pretreatment oxygen level measurements in spontaneous canine tumors 
on treatment outcome. 
Material and Methods: Data of pretreatment tumor oxygenation status and local tumor response after primary radiation thera-
py in a group of spontaneously occurring tumors in dogs (n = 52) was collected. Radiation therapy was given with curative 
(14–17 × 3–3.5 Gy) or palliative intent (3 × 8 Gy or 4–5 × 6 Gy). Progression-free interval and overall survival were correlated to 
polarographically measured tumor oxygenation status. 
Results: In the curatively irradiated group, tumors with median pO2 values ≤ 10 mmHg tended to have shorter median progres-
sion-free interval compared to better oxygenated tumors (246 vs. 739 days). The same trend could be shown for overall survival 
(330 vs. 745 days), indicating a cutoff value in this region. In the group treated with lower doses of radiation, the level of oxygen 
was no longer found to be of prognostic value; however, in this group hemoglobin had a significant impact on outcome. 
Conclusion: In curatively irradiated spontaneous canine tumors, tumor hypoxia was found to be a prognostic indicator, indepen-
dent of tumor histologies and volume. 
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Einfluss des prätherapeutischen Oxygenierungsstatus bei bestrahlten spontan auftretenden Tumoren des Hundes 
Hintergrund und Ziel: Das Ausmaß der Hypoxie in Primärtumoren beeinflusst das Ansprechen auf eine Therapie. Das Ziel der 
vorliegenden Studie war, den Zusammenhang zwischen dem prätherapeutischen Sauerstoffstatus und Ansprechen auf die Strah-
lentherapie bei Hunden zu untersuchen. 
Material und Methodik: Bei Hunden (n = 52) mit spontan auftretenden Tumoren, die entweder einer kurativen (14–17 × 3–3,5 Gy) 
oder einer palliativen Strahlentherapie (3 × 8 Gy oder 4–5 × 6 Gy) unterzogen wurden, wurde der prätherapeutische Sauerstoffpar-
tialdruck gemessen. Die progressionsfreie Zeit sowie die Gesamtüberlebenszeit nach Therapie wurden mit den polarographisch 
gemessenen Sauerstoffdaten korreliert (Tabelle 1; Abbildung 1).
Ergebnisse: In der kurativ bestrahlten Gruppe konnte gezeigt werden, dass Tumoren mit einem Median der pO2-Messwerte von 
≤ 10 mmHg eine kürzere progressionsfreie Zeit (246 vs. 739 Tage) und Gesamtüberlebenszeit hatten als besser oxygenierte Tumo-
ren (330 vs. 745 Tage; Abbildung 2). In der palliativ bestrahlten Tiergruppe konnte dieser Effekt nicht gezeigt werden, jedoch 
wurde ein Einfluss des Hämoglobins auf das Therapieergebnis offensichtlich (Tabellen 2 bis 4).
Schlussfolgerung: Bei kurativ bestrahlten spontan auftretenden Tumoren des Hundes ist die Hypoxie ein von Histologie und 
Tumorvolumen unabhängiger prognostischer Faktor. 
Schlüsselwörter:  Hypoxie · Strahlentherapie · Polarographische Feinnadelsonden · Hund · Tumor 
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Introduction
Hypoxic conditions in tumors are known to modulate the sen-
sitivity of cancer cells to various treatment modalities [18, 19, 
29]. Radiation sensitivity, for example, decreases for cells in 
environments with pO2 values below mixed-venous blood 
(40 mmHg), and for values below 3–4 mmHg, the sensitivity 
is halved, compared to well-oxygenated tissues [38]. Tumor 
hypoxia, measured by invasive oxygen electrodes, has been 
found prognostic for tumor control and treatment outcome in 
a variety of human tumors [6, 12, 14, 19, 27, 28, 33, 40]. 
The presence, prevalence and distribution of hypoxic tu-
mor cells in spontaneous canine tumors have been detected by 
several techniques and related to tumor and patient character-
istics [2, 11, 31]. The binding of nitroimidazoles, hypoxic 
cell-marking substances, has been studied and has proven the 
presence of hypoxia in canine tumors [11]. Imaging techniques 
that quantitate hypoxic cells, using a nitroimidazole compound 
labeled with a radioisotope [18F]-misonidazole (FMISO), have 
been described [15, 32]. Bruehlmeier et al. used a similar tech-
nique to describe tumor hypoxia and perfusion in spontane-
ous canine tumors [7, 32]. Achermann et al. as well as Brur-
berg et al. recently documented the presence and changes of 
hypoxia in spontaneous canine tumors during fractionated ra-
diotherapy using invasive polarographic needle electrodes 
and OxyLite fluorescence probes, respectively [2, 8]. 
The influence of tumor oxygenation status on the re-
sponse to radiation therapy has not been described for sponta-
neous canine tumors. In this study we aimed at investigating 
the impact of pretreatment oxygenation level measurements 
in spontaneous canine tumors on therapy outcome, including 
response to radiation therapy, progression-free interval (PFI) 
and overall survival. We also tried to identify whether there is 
an oxygen partial pressure (pO2) to be found that appears to 
be a cutoff level indicative of prognosis between hypoxic and 
less hypoxic tumors. Furthermore, the dependence of influ-
encing factors such as dose of radiation, hematologic parame-
ters and tumor parameters was tested. 
Material and Methods 
Patients 
Dogs with spontaneously originating malignant tumors treat-
ed with fractionated irradiation were included in the study. All 
dogs were client-owned pets that were presented for tumor 
therapy to the Section of Diagnostic Imaging and Radiation 
Oncology of the Vetsuisse Faculty, University of Zurich, Swit-
zerland, from 2001 to 2004. Prior to treatment all dogs under-
went diagnostic work-up as indicated for staging of the dis-
ease. All patients presented with macroscopic tumors. Primary 
tumor site and size, histopathologic differentiation and stag-
ing information were obtained. 
Radiation Therapy 
All dogs were treated with external-beam megavoltage radia-
tion. Radiation was delivered with a 6-MV linear accelerator 
(Dynaray LA20; ABB/VARIAN) using 6-MV photons or 
9- to 16-MeV electrons, as appropriate. Individualized treat-
ment plans were generated using a 3-D computer treatment 
planning system (Varian CadPlan® 6.0.8; Figure 1). Treatment 
protocols were delivered either with palliative (3 × 8 Gy on 
days 0, 7, 21 or 4–5 × 6 Gy, applied biweekly) or curative intent 
(14–17 × 3–3.5 Gy, applied in four or five fractions per week), 
resulting in an overall treatment time of 3.5 weeks. 
pO2 Measurements and Tumor Volumes 
Polarographic tumor oxygen partial pressure measurements 
were performed as previously described in dogs by Acher-
mann et al. [1, 2]. Tumor volume was calculated based on the 
formula: π/6 × height × width × depth, which approximately 
describes the volume of an ellipsoid [35]. The hypoxic sub-
volume (HSV) was calculated by the formula: volume (cm3) 
× hypoxic fraction (% of pO2 values ≤ 5 mmHg) [34]. 
Patient Follow-up and Response to Treatment 
Regular follow-up clinical reexaminations were performed in 
order to collect information about general performance and tu-
mor status. Responses are defined in Table 1 and evaluated at 
the end of therapy, at 3 weeks or 3 months depending on tumor 
histology. Routine clinical follow-up visits were made every 6 
months thereafter. PFI was determined from the first time point 
of tumor regression to the time of progressive disease, indepen-
dent of completeness of previous response. Overall survival 
time was determined from the beginning of radiation therapy. 
Statistical Analysis 
Description of patient data, other than overall survival times, 
is given by mean (± SD [standard deviation]) unless otherwise 
Figure 1. Three-field treatment plan for an oral squamous cell carcino-
ma. Transverse CT image at the level of the eyes with dose distribu-
tions. 
Abbildung 1. Therapieplan mit drei Feldern zur Behandlung eines 
oralen Plattenepithelkarzinoms. Transversale CT-Aufnahme mit Dosis-
verteilung auf Höhe der Augen. 
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Table 1. Patient and tumor characteristics, median pO2 and response to therapy. CR: complete response (complete disappearance of all measurable 
and evaluable disease based on physical examination or diagnostic imaging); PD: progressive disease (increase in tumor measurements of ≥ 25%, 
or the development of new lesions); PFI: progression-free interval; PR: partial remission (reduction by ≥ 50%, with no new lesions developing); 
SD: stable disease (< 50% decrease or < 25% increase).  
Tabelle 1. Patienten- und Tumordaten, Median der pO2-Messwerte und Ansprechen auf die Therapie. CR: komplette Remission (vollständige Rück-
bildung des messbaren Tumors, evaluiert in klinischer Untersuchung und bildgebenden Verfahren); PD: progressive Erkrankung (Zunahme des 
Tumorvolumens von ≥ 25% oder Entwicklung neuer Läsionen); PFI: progressionsfreie Zeit; PR: partielle Remission (Rückbildung von ≥ 50%, keine 
Entwicklung neuer Läsionen); SD: stabile Erkrankung (< 50% Reduktion der Tumorgröße bzw. < 25% Zunahme). 
Patient # Histology Location Volume  Hypoxic sub- Median  Response PFI  Overall
   (cm3) volume (cm3) pO2 (mmHg)  (days) survival (days)
Curative treatment (n = 23)
  1 Squamous cell carcinoma Oral cavity   28.3     1.5 48 CR    529    733
  2 Bone sarcoma Oral cavity   17.3     2.1 29 CR    394    472
  3 Squamous cell carcinoma Oral cavity     6.3     0.7 36 CR 1,134 1,233a
  4 Bone sarcoma Trunk 249.9 129.0   5 SD    246    246
  5 Fibrosarcoma Oral cavity   35.8   12.4 12 PR    739    739
  6 Fibrosarcoma Oral cavity     6.3     6.28   0 PR    111    125
  7 Fibrosarcoma Oral cavity   50.3   24.7   5 PR    540    847
  8 Acanthomatous epulis Oral cavity      1.6     0.3 23 CR    810    914a
  9 Acanthomatous epulis Oral cavity   10.5     4.4   6 CR    547a    547a
10 Fibrosarcoma Oral cavity     4.8     2.4   5 PR    195    195
11 Infiltrative lipoma Trunk 148.9     6.7 20 CR    333a    333a
12 Squamous cell carcinoma Oral cavity     3.2     0 11 PR    312a    312a
13 Hemangiopericytoma Limb 347.0     0 49 PR    312a    312a
14 Squamous cell carcinoma Oral cavity     5.4     0.6   6 CR      83    243a
15 Squamous cell carcinoma Oral cavity     0.3     0 20 CR    233a    241a
16 Fibrosarcoma Oral cavity     2.7     0 11 CR    220a    220a
17 Squamous cell carcinoma Oral cavity   13.1     0 31 CR    158a    158a
18 Spindle cell sarcoma Oral cavity   15.7     6.5 15 PR      64      64
19 Squamous cell carcinoma Oral cavity     2.6     0.1 24 CR    899a    899a
20 Fibrosarcoma  Oral cavity   49.4   37.4   4 PR    255    330
21 Squamous cell carcinoma Oral cavity     9.2     0.5 22 SD      30      30
22 Fibrosarcoma Oral cavity   25.6     6.9   7 CR      57a      57a
23 Hemangiopericytoma Limb   82.2     0.7 11 CR    174a    174
Palliative treatment (n = 29)
24 Malignant melanoma Oral cavity   24.5   20.4   1 PR      52      52
25 Fibrosarcoma Oral cavity   31.4   26.7   0 PR    139    169
26 Bone sarcoma Oral cavity   54.6   32.8   3 PR    159    159
27 Fibrosarcoma Skull   40.3   20   0 SD      45      88
28 Myxosarcoma Limb   83.6   21.1 42 SD    106    196
29 Hemangiopericytoma Limb 100.5   23.3 30 SD      90      90
30 Fibrosarcoma Limb 111.9 100.2   0 SD    420    420
31 Bone sarcoma Oral cavity   64.9   18.7 14 PR    104    104
32 Malignant melanoma Oral cavity     2.1     1.2   3 PR    456    833
33 Histiocytic sarcoma Limb 161.3   59.7   6 SD      78      83
34 Spindle cell sarcoma Oral cavity   12.8   10.1   2 PR    218    311
35 Histiocytic sarcoma Limb   65.4   58.2   0 PD      20      47
36 Fibrosarcoma Skull 149.7 126.7   2 PR      52      52a
37 Bone sarcoma Oral cavity   22.0   22.0   0 CR    365    498
38 Malignant melanoma Oral cavity   26.4   20.1   1 PR      32    109
39 Hemangiosarcoma Skull   90.0     0 13 PR      32      32
40 Malignant melanoma Oral cavity     4.2     1.0 15 SD      61      61a
41 Fibrosarcoma Limb 164.9     0 20 PR    179a    179a
42 Myxosarcoma Limb 356.2   54.2 14 SD    428    488
43 Myxosarcoma Skull 113.1 113.1   0 CR    147    311
44 Malignant fibrous histiocytoma Skull   65.4   42.2   0 CR      87      87
45 Histiocytic sarcoma Limb 331.8 308.7   1 SD      31      31
46 Histiocytic sarcoma Limb   53.6   41.0   0 SD      53      53
47 Fibrosarcoma Skull     6.3     5.6   0 PR    236    310
48 Malignant melanoma Oral cavity   15.7   15.4   0 PR    137    301
49 Histiocytic sarcoma Oral cavity   12.6     0 50 CR    177a    207a
50 Malignant melanoma Oral cavity   15.7     0 55 PR      65a      65a
51 Malignant melanoma Oral cavity     0.2   0.1   1 CR    389a    389a
52 Malignant melanoma Oral cavity   17.0   0 56 SD      50    173a
aDogs still progression-free and/or alive at the time of analysis were censored
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specified. Endpoints after radiation therapy were recorded as: 
(1) response to initial therapy, (2) PFI, and (3) overall surviv-
al. Median PFI and overall survival times were reported to-
gether with the 95% confidence interval (95% CI). Deaths 
attributable to disease progression were considered events in 
the survival analysis. Dogs that received additional treatment, 
died of other causes, were still alive at the time of data evalua-
tion, or lost to follow-up, were censored. 
The influences of different tumor and patient characteris-
tics on descriptors of tumor oxygenation were evaluated by 
correlation (Wilcoxon rank test, Fisher’s exact probability 
test). PFI and overall survival were compared with respect to 
different tumor and patient characteristics by Kaplan-Meier 
method, log-rank and Breslow-Gehan-Wilcoxon tests, uni-
variate proportional hazards and multiple Cox regression 
analysis. Distribution in HSV and tumor volumes were 
skewed; thus logarithmically transformed values were used 
rather than raw measurements. In all calculations, significance 
was assumed at a p-value of < 0.05. For statistical analysis, 
StatView 5.0.1 was used. 
Results 
Patients 
52 dogs with spontaneous malignant tumors were included in 
this series. Mean weight and age of the 24 female and 28 male 
dogs of various breeds at the time of diagnosis were 29.4 kg 
(range: 2.8–66 kg) and 9.3 years (range: 2–15 years), respec-
tively. Only one dog had clinical evidence of pulmonary me-
tastasis and none displayed a life-compromising disease 
other than the known cancer. The majority of the animals 
had sarcomas (n = 29), squamous cell carcinomas (n = 8), or 
malignant melanomas (n = 8). Most of the tumors were lo-
cated in the oral cavity (n = 33). The hematologic param-
eters were normally distributed. The mean hematocrit 
was 43.6% (range: 29–55%, normal: 
37–55%; p = 0.466), the hemoglobin 
(Hb) 15.2 g/dl (range: 10–26.6 g/dl, nor-
mal: 12–18 g/dl; p = 0.360). 
pO2 Measurements and 
Tumor Volumes 
38 tumors were measured with an Eppen-
dorf, 14 with a Phönix pO2 Histograph. 
The mean of all median pO2 values was 
low with 14 mmHg (range: 0–56 mmHg). 
52% (27/52) of all tumors had median 
pO2 values ≤ 10 mmHg; 42.5% of all 
pO2 readings were ≤ 5 mmHg and 36.3% 
of all pO2 readings were ≤ 2.5 mmHg. 
The mean tumor volume was 63.7 cm3 
(± 88.2 cm3). Although the tumor vol-
umes and the HSV of the sarcoma 
group were significantly larger than the 
ones of the group with other histologies 
(p = 0.0007 and p = 0.019), no correlation between tumor vol-
umes, hematologic parameters, and any of the oxygen param-
eters could be found. The relative frequency distribution of 
low oxygen levels in sarcoma and non-sarcoma histologies was 
not different; therefore for further analysis, the patients were 
split up according to their radiation treatment protocol. 
Treatment Protocols and Response to Treatment 
Initial therapy consisted of radiation (n = 52) given with cura-
tive (n = 23) or palliative (n = 29) intent (mean total dose 
50.5 Gy [± 3.5 Gy] vs. 27.3 Gy [± 4.9 Gy]). Seven patients each 
received additional chemotherapy or surgery. Response to 
treatment was observed in 51/52 patients (98%). Complete 
response could be observed in 18/52 patients (35%), partial 
response in 21/52 (40%), stable disease in 12/52 (23%), and 
progressive disease was seen in one case (2%; Table 1). At the 
time of analysis 14 patients were free of progression and 19 
were still alive. Patients were followed up to death or the 
close-out date, and none was lost to follow-up. The mean and 
median follow-up times for patients still alive were 346 days 
(range: 52–1233 days) and 234 days, respectively. 25 patients 
died of tumor-related disease, four for other reasons, and in 
four cases cause of death could not be assessed. 
Progression-Free Interval and 
Overall Survival 
Univariate Models 
Curatively treated patients that experienced a complete re-
sponse after initial treatment had a median PFI of 810 days 
(95% CI 605–1,015 days), with non-complete response the 
PFI was 246 days (95% CI 198–293 days; p = 0.014). We found 
significant correlations between the percentages of pO2 vaues 
≤ 10, 5 and 2.5 mmHg and shorter duration of the PFI in 
the curatively treated patients (Table 2). PFI for curatively 
Table 2. Univariate proportional hazards Cox regression results for influences on progres-
sion-free interval. Hb: hemoglobin; HSV: hypoxic subvolume. 
Tabelle 2. Resultate für beeinflussende Faktoren auf das progressionsfreie Intervall (univariate 
Cox-Regression). Hb: Hämoglobin; HSV: hypoxisches Subvolumen. 
 Curative treatment (n = 23) Palliative treatment (n = 29)
Variable Coef. (SE) p-value Coef. (SE) p-value
Age   0.135 (0.136) p = 0.319 –0.036 (0.101) p = 0.717
lnVolume   0.170 (0.214) p = 0.427   0.186 (0.142) p = 0.190
lnHSV   0.375 (0.206) p = 0.068   0.266 (0.147) p = 0.069
Median pO2 (mmHg) –0.043 (0.028) p = 0.124 –0.007 (0.015) p = 0.646
% pO2 ≤ 10 mmHg   0.028 (0.013) p = 0.029*   0.005 (0.006) p = 0.401
% pO2 ≤ 5 mmHg   0.026 (0.011) p = 0.019*   0.006 (0.006) p = 0.351
% pO2 ≤ 2.5 mmHg   0.028 (0.011) p = 0.013*   0.005 (0.006) p = 0.412
Hb –0.462 (0.265) p = 0.081 –0.281 (0.114) p = 0.014*
Sarcoma
(Breslow-Gehan-Wilcoxon) p = 0.370  p = 0.149
*p < 0.05
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treated patients with median pO2 values > 10 mmHg was 739 
days (95% CI 561–916 days), for median pO2 values ≤ 10 
mmHg 246 days (95% CI 206–286 days; p = 0.083; Figure 2). 
For palliatively treated patients, the tumors had lower median 
pO2 values (p = 0.008); however, neither the median pO2 val-
ues, nor the amount of pO2 values ≤ 10, 5 and 2.5 mmHg of the 
tumors in the palliatively treated group influenced PFI. The 
Hb level was negatively correlated with the duration of the 
PFI in the palliatively treated group only (p = 0.014). An influ-
ence of the tumor group on the PFI could not be found. 
The median overall survival time for patients with initial 
curative treatment intent was significantly longer than for the 
palliatively treated group (733 days [95% CI 541–925 days] vs. 
196 days [95% CI 62–330 days]; p = 0.0011). Factors that influ-
ence overall survival are displayed in Table 3: for patients of the 
curatively treated group, high amounts of 
oxygen levels ≤ 5 or 2.5 mmHg resulted 
in a shorter overall survival time. Larger 
tumor volumes, HSV and low Hb levels 
were associated with shorter overall sur-
vival in the palliatively treated group. 
Multivariate Models 
Multiple stepwise forward and backward 
analyses showed that for PFI and overall 
survival in the patients of the curatively 
treated group, the oxygen values were 
the only prognostic factors. In the pallia-
tively treated group, PFI was influenced 
by Hb only, while overall survival was 
influenced by Hb levels, age and HSV 
(Table 4). 
Discussion 
This study found that the tumors with 
the highest number of pO2 values ≤ 10, 
5 and 2.5 mmHg were related to the poorest outcome regard-
ing PFI and overall survival for patients treated with curative 
intent. This finding was independent of tumor histology and 
volume. Also, a trend to longer PFI in tumors with median 
pO2 values > 10 mmHg could be shown, indicating a possible 
presence of a “cutoff” point in this region as described by 
Höckel et al. for human cervical cancers [18, 19]. 
Invasive oxygen electrode measurement studies have 
demonstrated the presence of hypoxia in a variety of human 
tumor types and sites [5, 6, 14, 24, 26–28], and a positive corre-
lation has been demonstrated between the presence of hypoxia 
and poor treatment outcome. Nordsmark et al. found tumor 
Table 3. Univariate proportional hazards Cox regression results for influences on survival. For 
abbreviations see Table 2. 
Tabelle 3. Resultate für beeinflussende Faktoren auf die Überlebenszeit (univariate Cox-
Regression). Abkürzungen s. Tabelle 2. 
 Curative treatment (n = 23) Palliative treatment (n = 29)
Variable Coef. (SE) p-value Coef. (SE) p-value 
Age   0.181 (0.152) p = 0.233 –0.129 (0.095) p = 0.174
lnVolume   0.315 (0.217) p = 0.080   0.337 (0.162) p = 0.038*
lnHSV   0.351 (0.201) p = 0.117   0.409 (0.176) p = 0.020*
Median pO2 (mmHg)  –0.037 (0.027) p = 0.167 –0.016 (0.018) p = 0.372
% pO2 ≤ 10 mmHg   0.025 (0.013) p = 0.056   0.005 (0.007) p = 0.501
% pO2 ≤ 5 mmHg   0.025 (0.011) p = 0.026*   0.004 (0.007) p = 0.504
% pO2 ≤ 2.5 mmHg   0.032 (0.013) p = 0.010*   0.004 (0.007) p = 0.595
Hb –0.309 (0.260) p = 0.235 –0.264 (0.135) p = 0.050*
Sarcoma
(Breslow-Gehan-Wilcoxon) p = 0.091  p = 0.426
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Figure 2. Kaplan-Meier cumulative plot for progression-free interval 
for curatively treated patients grouped by median pO2 values. Disease 
progression was considered an event. Dogs still alive or lost to fol-
low-up at the time of analysis were censored. +: censor times. 
Abbildung 2. Kaplan-Meier-Kurve für progressionsfreie Zeit bei kurativ 
behandelten Patienten, nach mittleren pO2-Werten gruppiert. Pro-
gression der Erkrankung wurde als Ereignis angesehen. Hunde, die zur 
Zeit der Berechnung noch lebten oder für Nachfolgeuntersuchungen 
nicht mehr zur Verfügung standen, wurden zensiert (+). 
Table 4. Multiple Cox regression analysis for influences on survival 
(palliative group only). For abbreviations see Table 2. 
Tabelle 4. Resultate für beeinflussende Faktoren auf die Überlebens-
zeit in der palliativ behandelten Gruppe (multiple Cox-Regression). 
Abkürzungen s. Tabelle 2. 
 Palliative treatment (n = 27) 
Variable Coef. (SE) p-value 
Age –0.201 (0.094) p = 0.033*
lnHSV   0.412 (0.205) p = 0.044*
Hb –0.365 (0.153) p = 0.017*
*p < 0.05
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oxygenation status using the % pO2 values ≤ 2.5 mmHg being 
predictive for locoregional control after primary radiotherapy 
in squamous cell carcinoma of the head and neck, while Brizel 
et al. found additional prognostic significance of pretreatment 
median pO2 (below or above 10 mmHg) in soft-tissue sarco-
mas [5, 6, 29]. However, Evans & Koch state, that the determi-
nation of the appropriate endpoint for needle electrode mea-
surements remains variable and unresolved [14]. 
We learned from other authors [30] and from our own ex-
perience [1, 2] that sarcomas tend to be severely hypoxic. 
Brizel et al. [5] described a longer disease-free survival for 
patients with sarcomas of median pO2 > 10 mmHg, and also 
found more hypoxia was present in larger tumors of mesen-
chymal origin [4]. However, in this regard no significance could 
be found in our data. Our findings are supported by findings 
first described by Vaupel et al. [39], stating that the occurrence 
of radiobiological hypoxia neither correlates with pathologic 
stage nor grade, and by the majority of published studies that 
do not support the paradigm that larger tumors are more hy-
poxic than smaller tumors [19, 20, 22, 23, 26, 34, 36]. 
In our study the amount of tumor hypoxia only influ-
enced the outcome in the group treated with curative intent 
(high doses) and not in the group that received lower total 
doses. A similar finding has been made by Brizel et al., where 
a higher radiation dose was related to longer overall survival, 
disease-free survival and duration of local-regional control 
[3]. Interestingly, in the palliatively treated group, where 
hypoxia was not found to be a determinant factor, the PFI 
and overall survival times correlated negatively with Hb 
levels. Some studies describe an association between anemia 
and poor tumor oxygenation, for example in rats [21], and 
worse prognoses for pre-, mid-, or end-treatment Hb levels 
for various tumor groups in humans have been reported [9, 
10, 13, 16, 17, 25, 33, 34, 37]. However, pretreatment Hb level 
is more likely an indicator of prognosis in terms of the pa-
tient’s general condition and the clinical relevance of Hb 
levels during and at the end of radiation therapy might be 
greater [13, 28]. 
Conclusion 
Our findings support the hypothesis that tumor hypoxia in 
spontaneous canine tumors has an impact on PFI and overall 
survival time. Canine tumors contain large amounts of hy-
poxic regions, and tumor hypoxia was found to be a strong 
prognostic indicator, independent of tumor histologies and 
volume. 
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